In this first episode of our three-part series, Prof. Jon Stone talks with Drs. Selma Aybek, David Perez, and Sarah Lidstone about FND diagnosis and exploring new phenotypes.

Related Links:

• FND Society at fndsociety.org
• FND guide for patients at neurosymptoms.org
• FND Hope at fndhope.org

Visit NPUb.org/Podcast for associated article links.

This episode was sponsored by the ExTINGUISH Trial for NMDAR Encephalitis: Call 844-4BRAIN5 to refer patients.

The August 2023 replay of past episodes showcases four interviews on functional neurologic disorders with Prof. Jon Stone. The episode begins with an interview by Prof. Jon Stone and Dr. Tamara Pringsheim with Wall Street Journal columnist Julie Jargon about the increased incidence of teen girls presenting with physical tics. The Recall episode continues with an interview with Drs. Tamara Pringsheim and Davide Martino about the latest updates on those functional tics and new diagnostic criteria. The third interview is with Dr. Tjerk Lagrand about how the diagnosis of functional seizures affects health care costs. The August Recall concludes with Dr. Mahinda Yogarajah about the importance of diagnosing and not misdiagnosing functional neurologic disorders.

Related Podcast Links:

1. Tik Tok Tics - https://directory.libsyn.com/episode/index/id/21928034
2. Functional Tic Update - https://directory.libsyn.com/episode/index/id/26601993
3. Health Care Utilization in FND - https://directory.libsyn.com/episode/index/id/25624821
4. Economic Cost of Functional Neurologic Disorders - https://directory.libsyn.com/episode/index/id/27225606

Related Article Links:

1. How Teens Recovered from the 'Tik Tok Tics' - https://www.nytimes.com/2023/02/13/health/tiktok-tics-gender-tourettes.html
2. Economic Cost of Functional Neurologic Disorders: A Systematic Review: https://n.neurology.org/content/early/2023/06/20/WNL.0000000000207388

Dr. Stacey Clardy talks with Dr. Natalia Rost about her experience speaking before the House of Representatives on the approval of lecanemab for the treatment of early Alzheimer disease.

Visit NPUb.org/Podcast for associated article links.

This episode was sponsored by the ExTINGUISH Trial for NMDAR Encephalitis: Call 844-4BRAIN5 to refer patients.

Dr. Justin Abbatemarco talks with Dr. Amel Karaa about the use of elamipretide in participants with genetically confirmed primary mitochondrial myopathies.

Read the related article in Neurology.

Visit NPUb.org/Podcast for associated article links.

Dr. Gordon Smith talks with Dr. Hoda Abdel-Hamid about the recent FDA approval for the first ever gene therapy for Duchenne muscular dystrophy.

Visit NPUb.org/Podcast for associated article links.

Dr. Kathryn Nevel talks with Dr. Ingo Mellinghoff about how vorasidenib improved progression-free survival in patients with Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas.

Read the related article in The New England Journal of Medicine.

Visit NPUb.org/Podcast for associated article links.

Dr. Jason Crowell talks with Prof. Jacob Elberg to provide neurologists with an insight into what goes on behind the scenes for patient-assistance programs.

Read the related article in The New England Journal of Medicine.

Visit NPUb.org/Podcast for associated article links.

Dr. Dan Ackerman talks with Dr. Thanh Nguyen about whether dual antiplatelet therapy is noninferior to intravenous thrombolysis among patients with minor nondisabling acute ischemic stroke.

Read the related article in JAMA.

Visit NPUb.org/Podcast for associated article links.

This episode was sponsored by the ExTINGUISH Trial for NMDAR Encephalitis: Call 844-4BRAIN5 to refer patients.

Dr. Stacey Clardy talks with Dr. Jonathan Graff-Radford about everything we need to know about corticobasal syndrome.

Read the related article in Neurology.

Visit NPUb.org/Podcast for associated article links.

This episode was sponsored by the ExTINGUISH Trial for NMDAR Encephalitis: Call 844-4BRAIN5 to refer patients.

Dr. Gordon Smith talks with Drs. Ruben P.A. van Eijk and Jordi van Unnik about the planning of interim analyses for clinical trials in ALS to maximize patient safety and minimize exposure to ineffective or harmful drugs.

Read the related article in Neurology.

Visit NPUb.org/Podcast for associated article links.